Expression profiling of prostate cancer tumors that are benign, clinically localized, or metastatic and refractory to hormones. Results compared to those obtained from immunoblotting to identify concordant changes in mRNA and protein levels.
GPL570:
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
Citation:
Varambally S, Yu J, Laxman B, Rhodes DR et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005 Nov;8(5):393-406. PMID: 16286247
